alpha-aminopyridine has been researched along with Pulmonary Disease, Chronic Obstructive in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (13.27) | 29.6817 |
| 2010's | 180 (79.65) | 24.3611 |
| 2020's | 16 (7.08) | 2.80 |
| Authors | Studies |
|---|---|
| Lea, S; Mathioudakis, AG; Singh, D | 1 |
| Egeberg, A; Gyldenløve, M | 1 |
| Bai, H; Zeng, S; Zou, M | 1 |
| De la Torre Gomar, FJ; Gimeno Castillo, J; Martínez de Lagrán Álvarez de Arcaya, Z; Menéndez Parrón, A | 1 |
| Page, C; Stolfa, I | 1 |
| Borghuis, T; Burgess, JK; Faiz, A; Mudiyanselage, SNHR; Nikolaev, VO; Schmidt, M; Timens, W; van den Berge, M; Zuo, H | 1 |
| Brankin, P; Bunton, DC; Bylesjo, M; Cheyne, L; Child, H; Cowan, K; Finch, M; Gourlay, EM; Hair, J; Low, C; Lynagh, S; Macluskie, G; Mallinson, D; McNeil, M; Palmer, CNA | 1 |
| Banno, A; Lakshmi, SP; Reddy, AT; Reddy, RC | 1 |
| Fortescue, R; Janjua, S; Poole, P | 1 |
| Finnegan, R; O'Grady, E; Ryan, S; Smyth, A; Williamson, M | 1 |
| Burghuber, OC; Funk, GC; Gleiss, A; Hartl, S; Kreibich, N; Urban, MH | 1 |
| An, TJ; Kim, JH; Kim, SY; Park, CK; Rhee, CK; Yoon, H | 1 |
| Brollo, M; Devillier, P; Grassin-Delyle, S; Naline, E; Salvator, H; Tenor, H | 1 |
| Bodkhe, S; Khan, T; Nikam, M; Patel, K; Sherje, AP; Suvarna, V | 1 |
| Williams, D | 1 |
| Baettig, U; Bahra, P; Bala, K; Brocklehurst, C; Budd, E; Butler, R; Cheung, AK; Choudhury, H; Collingwood, SP; Cox, B; Danahay, H; Edwards, L; Everatt, B; Glaenzel, U; Glotin, AL; Gosling, M; Grand, DL; Groot-Kormelink, P; Hall, E; Hatto, J; Howsham, C; Hughes, G; King, A; Koehler, J; Kulkarni, S; Lightfoot, M; Nicholls, I; Page, C; Pergl-Wilson, G; Popa, MO; Robinson, R; Rowlands, D; Sandham, DA; Sharp, T; Spendiff, M; Stanley, E; Steward, O; Taylor, RJ; Tranter, P; Wagner, T; Watson, H; Williams, G; Wright, P; Young, A | 1 |
| Chen, DD; Le Grange, JM; Zhang, JN; Zheng, XF; Zhou, LQ; Zhu, XL | 1 |
| Bruno, R; Claret, L; Facius, A; Krause, A; Lahu, G | 1 |
| Golpe, R; Gómez-Rodríguez, M | 1 |
| Hashim, Z; Khan, A; Nath, A | 1 |
| Calverley, PMA; Fabbri, LM; Martinez, FJ; Rabe, KF | 1 |
| Berra, G; Gianella, P; Glatz, N; Janssens, JP | 1 |
| Albert, RK; Anzueto, A; Calverley, PMA; Criner, GJ; Hurst, JR; Krishnan, JA; Miravitlles, M; Papi, A; Rabe, KF; Rigau, D; Sliwinski, P; Tonia, T; Vestbo, J; Wedzicha, JA; Wilson, KC | 1 |
| Chong, J; Leung, B; Poole, P | 2 |
| Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P | 1 |
| Benjamin, JT; Blackwell, TS; Cheng, DS; Du, RH; Gleaves, L; Guo, M; Han, W; McKissack, A; Polosukhin, VV; Richmond, BW; van der Meer, R; Zhang, Y | 1 |
| Chen, WY; Fang, ZX; Lu, WF; Lv, XD; Shen, LF; Yang, Q | 1 |
| Gao, Y; Liu, DY; Peng, D; Wang, XJ; Wang, ZG; Zhang, HM; Zhang, YX | 1 |
| Davidsen, JR; Henriksen, DP; Pottegård, A; Salvesen, ØNU | 1 |
| Barreiro, E; Casadevall, C; Gea, J; Pascual-Guardia, S; Puig-Vilanova, E; Salazar-Degracia, A | 1 |
| Aftab, B; Amir, N; Fayyaz, A; Hanif, M; Ijaz, H; Mustafa, MI; Qureshi, J; Rasul, A | 1 |
| Alagappan, VKT; Anzueto, A; Bagul, N; Calverley, PMA; Fabbri, LM; Martinez, FJ; McIvor, A; Pizzichini, E; Purkayastha, D; Rabe, KF; Reisner, C; Rennard, SI; Román, J; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Kardos, P; Mokros, I; Sauer, R; Vogelmeier, CF | 1 |
| Facius, A; Gardiner, P; Lahu, G; Marostica, E; Watz, H | 1 |
| Celli, BR | 1 |
| Chen, X; Chen, Y; Fan, J; Fan, L; Liu, S; Luo, P; Xu, X; Ye, J; You, D; Zhang, X | 1 |
| Davies, A; Gibson, D; Kiff, C; Purkayastha, D; Ruiz, S; Varol, N | 1 |
| Alagappan, VKT; Bagul, N; Baraldo, S; Biondini, D; Göhring, UM; Hanauer, G; Pedersen, F; Purkayastha, D; Rabe, KF; Román, J; Saetta, M; Watz, H | 1 |
| Han, MK | 1 |
| Ficker, JH; Graf, J; Jörres, RA; Lucke, T; Nowak, D; Vogelmeier, CF | 1 |
| Barnes, PJ; Davies, CM; Donnelly, LE; Dunne, AE; Fenwick, PS; Kawamatawong, T; Tullett, H | 1 |
| Lee, BC; Li, JD; Susuki-Miyata, S; Yan, C | 1 |
| Alexa, I; Alexa-Stratulat, T; Antohe, I; Antoniu, S; Arghir, O; Grigorescu, C | 1 |
| Fessler, MB | 1 |
| Al-Sajee, D; Gauvreau, GM; Yin, X | 1 |
| Carson, KA; Hansel, NN; Laube, BL; Paulin, LM; Sharpless, G | 1 |
| Davidson, HE; Pleasants, RA; Radlowski, PA | 1 |
| Bridgewood, C; Civelli, M; Facchinetti, F; Higham, A; Lea, S; Li, J; Metryka, A; Singh, D; Villetti, G | 1 |
| Kang, J; Lee, JS; Lee, SD; Lee, SW; Oh, YM; Park, TS | 1 |
| Bredenbröker, D; Calverley, PMA; Cooke, GE; Goehring, UM; Kowey, PR; Lakkis, H; Mosberg, H; Rabe, KF; Rowe, P; White, WB; Zhu, H | 1 |
| Jenkins, C; Leuppi, J; Osthoff, M | 1 |
| Gu, WJ; Pan, L; Yan, JH | 1 |
| Basma, H; Farid, M; Feghali-Bostwick, C; Gunji, Y; Ikari, J; Iwasawa, S; Liu, X; Michalski, JM; Nelson, AJ; Nogel, S; Park, JH; Rennard, SI; Schulte, N; Tenor, H; Toews, ML; Wang, X | 1 |
| Horna, O; Toyas, C | 1 |
| Giembycz, MA; Greer, S; Joshi, T; Newton, R; Page, CW; Yan, D | 1 |
| Siddiqui, S | 1 |
| Antoniu, SA | 3 |
| Beghè, B; Boschetto, P; Fabbri, LM; Nozzoli, C | 1 |
| Lone, NA; Oba, Y | 2 |
| White, WB | 1 |
| Tashkin, DP | 2 |
| Dharmarajan, S; Dinavahi, SS; Nyayapathy, S; Perumal, Y; Viswanadha, S | 1 |
| Brose, M; Calverley, PM; Dransfield, MT; Goehring, UM; Hanania, NA; Karpel, JP; Rowe, P; Zhu, H | 1 |
| Bai, C; Brose, M; Chen, P; Goehring, UM; Hui, F; Kang, J; Li, H; Richard, F; Wang, H; Yang, J; Zhao, L; Zheng, J; Zhong, N; Zhou, X | 1 |
| Facius, A; Lahu, G | 1 |
| Benipal, H; Kale-Pradhan, P; Lipari, M | 1 |
| Boyd, CM; Fain, K; Li, T; Puhan, MA; Singh, S; Varadhan, R; Weiss, CO; Yu, T | 1 |
| Barnes, NC; Rabe, KF; Saetta, M | 1 |
| Coyle, T | 1 |
| Bredenbröker, D; Brose, M; Calverley, PMA; Goehring, UM; Martinez, FJ; Rabe, KF; Wedzicha, JA | 2 |
| Calverley, P | 1 |
| Giembycz, MA; Newton, R | 1 |
| Cortijo, J; Guijarro, R; Milara, J; Peiró, T; Serrano, A; Tenor, H; Zaragozá, C | 1 |
| Gail, MH | 1 |
| Almudever, P; Cortijo, J; Freire, J; Lluch, J; Milara, J; Xiaozhong, Q | 1 |
| Chou, A; D'Urzo, AD | 1 |
| Bedert, L; Claes, R; De Backer, J; De Backer, W; Hufkens, A; Parizel, PM; Van Holsbeke, C; Vinchurkar, S; Vos, W | 1 |
| Rabe, KF; Suissa, S | 2 |
| Ho, N; Prasad, V; Rho, J | 3 |
| Song, SD; Tang, HF | 1 |
| Bredenbröker, D; Calverley, PM; Goehring, UM; Rennard, SI; Rowe, P; Sun, SX; Tourkodimitris, S | 1 |
| Sinopal'nikov, AI | 1 |
| Diez-Ferrer, M; Dorca, J; Huertas, D; López-Sánchez, M; Manresa, F; Montón, C; Muñoz-Esquerre, M; Pomares, X; Santos, S | 1 |
| Page, CP | 1 |
| Alonso-Garcia, M; Ballester, B; Cortijo, J; Freire, J; Milara, J; Morcillo, E; Morell, A; Qian, X; Sanz, C | 1 |
| Brose, M; Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF | 1 |
| Freire, J; Qian, X; Tarran, R; Tyrrell, J | 1 |
| Kai, H; Lee, BC; Li, JD; Miyata, M; Susuki-Miyata, S; Xu, H; Yan, C | 1 |
| Amin, A; Ellis, JJ; Howe, A; Moll, K; Sun, SX | 1 |
| Amin, AN; Fu, AZ; Huang, X; Sun, SX | 1 |
| Domvri, K; Hatzizisi, O; Kikidaki, V; Kioumis, I; Lampaki, S; Liaka, A; Organtzis, J; Papaioannou, A; Petridis, D; Porpodis, K; Tsirgogianni, K; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Boyd, CM; Puhan, MA; Ter Riet, G; Yu, T | 1 |
| Henry, MT; Hunt, EB; Kennedy, MP; Murphy, DM; Plant, BJ; Worndl, E | 1 |
| Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X | 1 |
| Garnock-Jones, KP | 1 |
| Jardim, JR; Stirbulov, R | 1 |
| Ghosh, B; Vanjare, NV | 1 |
| Cai, Q; Jain, R; Sun, SX; Tan, H | 1 |
| Droege, CA; Ernst, NE; Mulhall, AM; Panos, RJ; Zafar, MA | 1 |
| Amore, C; Beume, R; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Tenor, H; Totani, L | 1 |
| Corman, S; Gao, X; Huang, X; Shorr, AF; Sun, SX; Wan, Y | 1 |
| Calverley, P; Celli, BR; Chambers, M; Clark, JF; Hawkins, N; Scott, DA; Thompson, JC; Woods, B | 1 |
| Bodin, A; Boichot, E; Daude, M; Devillier, P; Gicquel, T; Lagente, V; Porto, LC; Tenor, H; Valença, S; Victoni, T | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Blalock, JE; Russell, DW; Wells, JM | 1 |
| Calverley, PM; Rabe, KF; Wedzicha, JA | 1 |
| Bhongir, RK; Egesten, A; Kasetty, G; Papareddy, P | 1 |
| Liang, BM; Liu, CT; Liu, D; Luo, J; Wang, K | 1 |
| Bedert, L; Claes, R; De Backer, J; De Backer, W; Hajian, B; Hufkens, A; Parizel, PM; Van Holsbeke, C; Vinchurkar, S; Vos, W | 1 |
| Abdolrasulnia, R; Blackwell, TS; Bordenstein, SR; Brucker, RM; Cheng, DS; Clark, PE; Du, RH; Gleaves, L; Han, W; Polosukhin, VV; Polosukhina, D; Richmond, BW; Zhang, Y | 1 |
| Hodgden, JD; Huser, JM | 1 |
| Calzetta, L; Cazzola, M; Matera, MG; Rogliani, P | 2 |
| Hong, YK; Lee, JS; Lee, SD; Lee, SW; Oh, YM; Park, TS | 1 |
| Cai, Q; Dai, X; Shao, N; Yang, M; Yuan, L | 1 |
| Anzueto, A; Martinez, FJ; McIvor, A; Pizzichini, E; Rabe, KF; Rennard, SI; Sethi, S; Siddiqui, S; Zhu, H | 1 |
| Alagappan, VK; Anzueto, A; Martinez, FJ; McIvor, A; Miller, CJ; Pizzichini, E; Rabe, KF; Reisner, C; Rekeda, L; Rennard, SI; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Hatipoglu, U; Lau, C; Mehta, AC | 1 |
| Donaldson, GC; Goehring, UM; Mackay, AJ; Nip, TK; Patel, ARC; Prasad, N; Sapsford, RJ; Singh, R; Wedzicha, JA | 1 |
| Anzueto, A; Miravitlles, M | 1 |
| Tatlicioğlu, T | 1 |
| Gauvreau, G; O'Byrne, PM | 1 |
| Brose, M; Bundschuh, DS; Calverley, PM; Fabbri, LM; Izquierdo-Alonso, JL; Martinez, FJ; Rabe, KF | 1 |
| Calverley, PM; Fabbri, LM; Goehring, UM; Kristiansen, S; Martinez, FJ; Rabe, KF | 1 |
| Bosch, DG; Case, SR; Chu, HW; Ge, XN; Martin, RJ; Minor, MN | 1 |
| Cazzola, M; Matera, MG; Picciolo, S | 1 |
| Wedzicha, JA | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Adnot, S; Beume, R; Hatzelmann, A; Lungarella, G; Morcillo, EJ; Sanjar, S; Schudt, C; Tenor, H | 1 |
| Giembycz, MA; Gross, NJ; Rennard, SI | 1 |
| Gillissen, A; Häussermann, A | 1 |
| Rabe, KF | 2 |
| Kreutzkamp, B | 1 |
| Sanford, M | 1 |
| Field, SK; Giembycz, MA | 1 |
| Diletti, E; Elmlinger, M; Facius, A; Hünnemeyer, A; Lahu, G; McCracken, N; Ruth, P; Zech, K | 1 |
| Cazzola, M | 1 |
| Beghé, B; Fabbri, LM; Kirkpatrick, P; Yasothan, U | 1 |
| Calverley, PM; Ulrik, CS | 1 |
| Chisholm, A; Crockett, A; Jones, R; Price, D; Ryan, D | 1 |
| Aparicio, J; Izquierdo, JL | 1 |
| Bonar, SL; Brustkern, SJ; Chen, NX; Christine, L; Heier, RF; Hu, Y; Huang, HC; Kishore, NN; Kurumbail, RG; Lennon, PJ; Li, X; Mathialagan, S; Poda, GI; Reding, MT; Selness, SR; Sommers, CD; Venkatraman, N; Wolfson, SG; Xie, J | 1 |
| Bredenbröker, D; Calverley, PM; Goehring, UM; Martinez, FJ; Rennard, SI | 1 |
| Cortijo Gimeno, J; Morcillo Sánchez, E | 1 |
| Izquierdo Alonso, JL | 3 |
| Agustí, A | 1 |
| Cortijo Gimeno, J | 1 |
| Martínez, FJ | 1 |
| Rochat, T | 1 |
| Chazan, RC | 1 |
| Black, PN; Chong, J; Leung, B; Poole, P | 1 |
| Almagro Mena, P | 1 |
| Bateman, ED; Bredenbröker, D; Brose, M; Calverley, PM; Fabbri, LM; Goehring, UM; Rabe, KF | 1 |
| Puhan, M | 1 |
| Bredenbröker, D; Goehring, UM; Hui, DS; Kuo, HP; Kwa, KH; Lee, SD; Mahayiddin, AA; Roa, CC | 1 |
| Bredenbröker, D; Brose, M; O'Donnell, DE; Webb, KA | 1 |
| Banerjee, R; Cheng, D; Marynchenko, M; Mocarski, M; Sun, SX; Wu, EQ; Yin, D; Yu, AP | 1 |
| Erdmann, E; Michels, G; Pfister, R | 1 |
| Hünnemeyer, A; Lahu, G; Nassr, N | 1 |
| Şenyiğit, A; Sezgi, C | 1 |
| Blasco, LM | 2 |
| Hamilton, LA; Hughes, A; Pinner, NA | 1 |
| Vetter, C | 1 |
| Gupta, S | 1 |
| Kelly Freeman, ML | 1 |
| Pham, NT; Reid, DJ | 1 |
| Hertel, N; Humphreys, S; Jameson, K; Kotchie, RW; Radford, M; Samyshkin, Y | 1 |
| Aoshiba, K; Azuma, A; Mizushima, T; Sato, K; Tanaka, K | 1 |
| Calero, C; Gutiérrez, C; López-Campos, JL | 1 |
| Almagro, P; Ancochea, J; Calle, M; López-Campos, JL; Miravitlles, M; Molina, J; Piñera, P; Quintano, JA; Riesco, JA; Simón, A; Soler-Cataluña, JJ; Soriano, JB; Trigueros, JA | 1 |
| Bredenbröker, D; Brose, M; Fabbri, LM; Göke, B; Rabe, KF; Teichmann, P; Wouters, EF | 1 |
| Laurenzi, M | 1 |
| Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF | 1 |
| Kullak-Ublick, GA; Leuppi, JD; Taegtmeyer, AB | 1 |
| Greulich, T; Koczulla, AR; Vogelmeier, C | 1 |
| Shmelev, EI; Shmeleva, NM | 1 |
| Basma, H; Fahrid, M; Gunji, Y; Holz, O; Kanaji, N; Liu, X; Magnussen, H; Michalski, J; Muller, KC; Nakanishi, M; Nelson, A; Nogel, S; Rabe, KF; Rennard, SI; Sato, T; Toews, ML; Wang, X | 1 |
| Lundquist, LM; Metzger, NL | 1 |
| Ehlken, B; Kotchie, R; Magnussen, H; Nowak, D; Wecht, S | 1 |
| Huang, L; Lai, K; Li, X; Liu, A; Luo, Z; Mao, F; Shan, W; Wang, Z; Xie, J | 1 |
| Haefliger, S; Ledderhose, S; Radford, M; Samyshkin, Y; Schlunegger, M | 1 |
| Giembycz, MA; Joshi, T; Moodley, T; Newton, R; Rider, CF; Sharma, P; Wilson, SM; Yan, D | 1 |
| Bateman, ED; Briggs, AH; Kotchie, RW; Mörk, AC; Samyshkin, Y | 1 |
| Giembycz, MA | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Vignola, AM | 1 |
| Belleguic, C; Cupif, JF; David, M; Depince, A; Gouault, N; Martin-Chouly, CA; Pinel, B | 1 |
| Hanania, NA; Soto, FJ | 1 |
| Cortijo, J; Morcillo, EJ; Sanz, MJ | 1 |
| Bergmann, JF | 1 |
| Eller, P; Pechlaner, C | 1 |
| Morice, AH | 1 |
| Vassiliou, V | 1 |
| Bhowmik, A; Boyd, AE; Rajakulasingam, K | 1 |
| Burnet, M; Guse, JH; Gutke, HJ; Khobzaoui, M; Renukappa-Gutke, T | 1 |
| Cowan, C | 1 |
| Fan Chung, K | 1 |
| Doggrell, SA | 1 |
| Gagnon, JM; Karish, SB | 1 |
| Bredenbroeker, D; Calverley, PM; Fabbri, LM; McIvor, A; Sanchez-Toril, F; Teichmann, P | 1 |
| Bethke, TD; Bredenbröker, D; Gauw, SA; Grootendorst, DC; Hiemstra, PS; Hospers, JJ; Rabe, KF; Sterk, PJ; Verhoosel, RM | 1 |
| Caeser, M; Calverley, PM; Lindemann, M; Rutten-van Mölken, MP; van Nooten, FE | 1 |
| Cui, X; Wang, D | 1 |
| Boswell-Smith, V; Spina, D | 1 |
| Field, SK | 1 |
| Fitzgerald, M; Sturton, G | 1 |
82 review(s) available for alpha-aminopyridine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclopropanes; Humans; Inflammation; Isoquinolines; para-Aminobenzoates; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrimidinones; Sulfonamides | 2021 |
Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Diarrhea; Disease Progression; Headache; Humans; Pulmonary Disease, Chronic Obstructive | 2022 |
Oral roflumilast as a therapeutic option for psoriasis, what role does it have? Case report and literature review.
Topics: Administration, Oral; Aminopyridines; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2023 |
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Diarrhea; Disease Progression; Forced Expiratory Volume; Humans; Middle Aged; Nitriles; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Vital Capacity | 2020 |
Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory System; Treatment Outcome | 2020 |
The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Pharmacists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2022 |
[New therapeutic options in pulmonary diseases in 2016 : focus on asthma, COPD and idiopathic pulmonary fibrosis (IPF)].
Topics: Aminopyridines; Asthma; Benzamides; Cyclopropanes; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases; Pulmonary Disease, Chronic Obstructive; Pulmonary Medicine; Therapies, Investigational | 2017 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Topics: Airway Remodeling; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Interleukin-17; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Hospitalization; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2019 |
Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Budesonide; Cyclopropanes; Fluticasone; Formoterol Fumarate; Humans; Ipratropium; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Recurrence; Salmeterol Xinafoate; Theophylline; Tiotropium Bromide | 2016 |
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Topics: Aminopyridines; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2019 |
Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Female; Humans; Nursing Homes; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; United States | 2019 |
Chronic obstructive pulmonary disease--a treatable disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Breathing Exercises; Bronchodilator Agents; Cyclopropanes; Disease Progression; Humans; Muscarinic Antagonists; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pneumonectomy; Pulmonary Disease, Chronic Obstructive; Smoking Cessation | 2013 |
Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Vital Capacity | 2014 |
Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking | 2014 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2013 |
Roflumilast in the management of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Approval; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Spirometry; United States; United States Food and Drug Administration | 2013 |
Current drug treatment, chronic and acute.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aminopyridines; Anti-Bacterial Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; Inflammation; Inflammatory Bowel Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfones; Thalidomide; Thiazoles | 2014 |
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Dyspnea; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
[Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Controlled Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Humans; Molecular Targeted Therapy; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Theophylline | 2014 |
Roflumilast: A Review in COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Tolerance; Humans; Pulmonary Disease, Chronic Obstructive | 2015 |
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Delivery Systems; Drug Design; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests | 2015 |
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Albuterol; Aminopyridines; Beclomethasone; Benzamides; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Cyclopropanes; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Ipratropium; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Survival Rate; Theophylline; Tiotropium Bromide; Triamcinolone | 2015 |
Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype.
Topics: Aminopyridines; Azithromycin; Benzamides; Cyclopropanes; Humans; Neutrophils; Phenotype; Pulmonary Disease, Chronic Obstructive | 2016 |
Roflumilast: a review of its use in the treatment of COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Symptom Flare Up | 2016 |
Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Risk Factors; Severity of Illness Index; Treatment Outcome | 2016 |
Clinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?
Topics: Adult; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Patient Acuity; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests | 2016 |
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design | 2016 |
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Medication Adherence; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Topics: Aminopyridines; Benzamides; Chi-Square Distribution; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Lung; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Severity of Illness Index; Spirometry; Treatment Outcome; Vital Capacity | 2016 |
What is the role of roflumilast in chronic obstructive pulmonary disease?
Topics: Aminopyridines; Benzamides; Cyclic AMP; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2017 |
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic AMP; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
Topics: Administration, Inhalation; Administration, Oral; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Forced Expiratory Volume; Humans; Lung; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Severity of Illness Index; Smoking Prevention; Treatment Outcome | 2010 |
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Drug Evaluation, Preclinical; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Topics: Aminopyridines; Benzamides; Clinical Trials as Topic; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
[Diseases of the lung and air passages 2010].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Indans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Phosphodiesterase 4 Inhibitors; Pneumonia, Bacterial; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2010 |
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests | 2010 |
Roflumilast: in chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Topics: Adult; Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Respiratory Function Tests; Severity of Illness Index | 2010 |
Roflumilast: clinical benefit in patients suffering from COPD.
Topics: Aminopyridines; Benzamides; Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2010 |
The use of roflumilast in COPD: a primary care perspective.
Topics: Adult; Aminopyridines; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Primary Health Care; Pulmonary Disease, Chronic Obstructive | 2010 |
Roflumilast for COPD.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Topics: Administration, Oral; Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Clinical Trials, Phase III as Topic; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Phosphodiesterase 4 Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
[Pharmacological profile of roflumilast].
Topics: Airway Remodeling; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cell Division; Cilia; Cyclopropanes; Drug Evaluation, Preclinical; Fibroblasts; Humans; Hypertension, Pulmonary; Macrophages; Mice; Molecular Structure; Mucus; Myocytes, Smooth Muscle; Neutrophils; Nicotiana; Oxidants; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Rats; Smoke | 2010 |
[Clinical profile of roflumilast].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Mice; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Rats; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Weight Loss | 2010 |
[Impact of new therapeutic options in COPD].
Topics: Aminopyridines; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Drugs, Investigational; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Smoking Cessation | 2010 |
[Phosphodiesterase 4 inhibitors: a new pharmacologic group in the treatment of chronic inflammation of the airways].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cilia; Cyclic AMP; Cyclic GMP; Cyclopropanes; Humans; Inflammation; Isoenzymes; Mucins; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Circulation; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Second Messenger Systems | 2010 |
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Inflammation; Multicenter Studies as Topic; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss | 2010 |
Roflumilast for severe COPD?
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2011 |
New therapeutic options in the management of COPD - focus on roflumilast.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Treatment Outcome | 2011 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2011 |
[Phosphodiesterase-4 inhibitors: roflumilast].
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide | 2011 |
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Contraindications; Cyclopropanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Mucociliary Clearance; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking | 2011 |
Pharmacokinetic evaluation of roflumilast.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].
Topics: Administration, Oral; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2012 |
Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
A review of the advances in chronic obstructive pulmonary disease treatment.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Female; Humans; Lung; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Treatment Outcome | 2013 |
Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Interactions; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
PDE4 inhibitors in COPD--a more selective approach to treatment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rolipram; Theophylline; Treatment Outcome | 2004 |
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Indoles; Inflammation; Lung; Nitriles; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2005 |
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Carboxylic Acids; Cell Adhesion Molecules; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2005 |
AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Topical; Amides; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dermatitis, Atopic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Indoles; Inflammation; Lipopolysaccharides; Ovalbumin; Phosphodiesterase Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Structure-Activity Relationship | 2005 |
Phosphodiesterase inhibitors in airways disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Carboxylic Acids; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Isoenzymes; Nitriles; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2006 |
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2006 |
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Costs; Drug Interactions; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2006 |
Evaluation of PDE4 inhibition for COPD.
Topics: Aminopyridines; Benzamides; Calcium Channel Blockers; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Circulation; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2006 |
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Humans; Lung; Nausea; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory System Agents; Treatment Outcome; Vomiting | 2007 |
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
Topics: Administration, Oral; Aminopyridines; Asthma; Benzamides; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Carboxylic Acids; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
34 trial(s) available for alpha-aminopyridine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.
Topics: Aged; Aminopyridines; Benzamides; Biomarkers; Cyclopropanes; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Intention to Treat Analysis; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Vascular Stiffness | 2021 |
Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Clinical Trials as Topic; Computer Simulation; Cyclopropanes; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2017 |
Effect of roflumilast in patients with severe COPD and a history of hospitalisation.
Topics: Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Respiration Disorders; Treatment Outcome | 2017 |
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Topics: Administration, Inhalation; Administration, Oral; Aged; Albuterol; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Exercise Tolerance; Female; Glucocorticoids; Glycopyrrolate; Humans; Lung Volume Measurements; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pregnenediones; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2018 |
Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests; Surveys and Questionnaires | 2018 |
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2018 |
Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Female; Forced Expiratory Volume; Germany; Health Status; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Monitoring; Drug Tolerance; Humans; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Topics: Aged; Aminopyridines; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzamides; Biopsy; Bronchodilator Agents; CD8-Positive T-Lymphocytes; Cyclopropanes; Double-Blind Method; Eosinophils; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Mucous Membrane; Pulmonary Disease, Chronic Obstructive; Respiratory System | 2018 |
Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Tobacco Smoking | 2019 |
Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
Topics: Age Factors; Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Medication Adherence; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Risk Factors; Seoul; Single-Blind Method; Time Factors; Treatment Outcome | 2019 |
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Switzerland; Treatment Outcome | 2013 |
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome; White People | 2014 |
Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast.
Topics: Aminopyridines; Benzamides; Biomarkers; Biopsy; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cholinergic Agents; Cyclopropanes; Exercise Tolerance; Humans; Lung; Phenotype; Phosphodiesterase 4 Inhibitors; Plethysmography; Pulmonary Disease, Chronic Obstructive; Spirometry; Treatment Outcome | 2014 |
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchodilator Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Vital Capacity | 2015 |
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Double-Blind Method; Epoxide Hydrolases; Exercise Tolerance; Female; Forced Expiratory Volume; Glycine; Humans; Inflammation; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Proline; Prolyl Oligopeptidases; Pulmonary Disease, Chronic Obstructive; Quality of Life; Serine Endopeptidases; Signal Transduction; Spirometry; Sputum; Treatment Outcome; Vital Capacity | 2015 |
Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Ventilation; Respiratory Function Tests; Severity of Illness Index; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Republic of Korea; Respiratory Function Tests; Treatment Outcome | 2016 |
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index | 2016 |
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Leukocyte Count; London; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sputum; Treatment Outcome | 2017 |
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Topics: Administration, Inhalation; Administration, Oral; Aged; Albuterol; Aminopyridines; Analysis of Variance; Benzamides; Bronchodilator Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Smoking; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2009 |
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Aminopyridines; Analysis of Variance; Benzamides; Cholinergic Antagonists; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Severity of Illness Index; Smoking; Treatment Outcome; Vital Capacity | 2009 |
Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Dyspnea; Female; Humans; Lung; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Regression Analysis | 2011 |
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anti-Inflammatory Agents; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Treatment Outcome; Vital Capacity | 2011 |
Physiological effects of roflumilast at rest and during exercise in COPD.
Topics: Aged; Airway Resistance; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Administration Schedule; Dyspnea; Exercise; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Physical Endurance; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Rest; Severity of Illness Index | 2012 |
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cyclopropanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycated Hemoglobin; Glycerol; Homeostasis; Humans; Insulin; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sample Size | 2012 |
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Topics: Adrenal Cortex Hormones; Adult; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Poisson Distribution; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index; Treatment Outcome | 2012 |
Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Diarrhea; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss | 2013 |
[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Germany; Health Care Costs; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Topics: Aged; Aminopyridines; Benzamides; Cohort Studies; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Health Status; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2007 |
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Topics: Aged; Aminopyridines; Benzamides; Biomarkers; Cell Count; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Eosinophils; Female; Forced Expiratory Volume; Humans; Male; Microcirculation; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sputum | 2007 |
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Topics: Aged; Aminopyridines; Benzamides; Cost-Benefit Analysis; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2007 |
110 other study(ies) available for alpha-aminopyridine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?
Topics: Aminopyridines; Chronic Disease; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2022 |
Phosphodiesterase inhibitors and lung diseases.
Topics: Aminopyridines; Humans; Lung Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2023 |
Cigarette smoke exposure alters phosphodiesterases in human structural lung cells.
Topics: Adult; Aminopyridines; Benzamides; Cyclopropanes; Female; Gene Expression; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive; RNA, Messenger; Smoke; Smoking; Tobacco Products | 2020 |
Application of pharmacogenomics and bioinformatics to exemplify the utility of human ex vivo organoculture models in the field of precision medicine.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Exome Sequencing; Fluticasone; Formoterol Fumarate; Genomics; Humans; Lung; MicroRNAs; Models, Biological; Organ Culture Techniques; Pharmacogenomic Variants; Precision Medicine; Pulmonary Disease, Chronic Obstructive; State Medicine | 2019 |
Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Topics: Aminopyridines; Benzamides; Cells, Cultured; Cyclopropanes; Dexamethasone; Drug Resistance; Epithelial Cells; Glucocorticoids; Humans; Inflammation Mediators; Interleukin-8; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Glucocorticoid; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Up-Regulation | 2020 |
Evidence of Small Airways Disease and the Immediate Effects of Lumacaftor/Ivacaftor in Children with Cystic Fibrosis.
Topics: Adolescent; Airway Remodeling; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Negative Results; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Risk Factors | 2020 |
The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation.
Topics: Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2021 |
Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist.
Topics: Aminopyridines; Benzamides; Bronchi; Bronchodilator Agents; Cyclopropanes; Female; Formoterol Fumarate; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2021 |
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Topics: Administration, Oral; Aminopyridines; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Drug Evaluation, Preclinical; Gene Deletion; Half-Life; Humans; Protein Binding; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship | 2021 |
Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Disease Models, Animal; Histone Deacetylase 2; Interleukin-8; Lung; Male; Mice, Inbred C57BL; Nicotiana; Pentoxifylline; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Smoke; Smoking; Theophylline; Tumor Necrosis Factor-alpha | 2021 |
Intolerance to roflumilast in real-life clinical practice.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Female; Gastrointestinal Diseases; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Sleep Initiation and Maintenance Disorders | 2017 |
Is Concomitant Use of Theophylline and Roflumilast Really Contraindicated?
Topics: Aminopyridines; Benzamides; Cyclopropanes; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Theophylline | 2017 |
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Fluoroquinolones; Humans; Macrolides; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Societies, Medical; United States | 2017 |
Bacterial-derived Neutrophilic Inflammation Drives Lung Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.
Topics: Airway Remodeling; Aminopyridines; Animals; Bacillus; Benzamides; Cyclopropanes; Disease Models, Animal; Mice, Inbred C57BL; Mice, Mutant Strains; Neutrophils; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Receptors, Cell Surface | 2018 |
Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study.
Topics: Adolescent; Adult; Aged; Aminopyridines; Benzamides; Cyclopropanes; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Registries; Young Adult | 2018 |
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Topics: Aminopyridines; Autophagy; Benzamides; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Female; Humans; Male; Middle Aged; Muscle Fibers, Skeletal; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; Phosphodiesterase 4 Inhibitors; Proteolysis; Pulmonary Disease, Chronic Obstructive | 2018 |
Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2018 |
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Topics: Administration, Inhalation; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; United Kingdom | 2018 |
Roflumilast for eosinophilic chronic obstructive pulmonary disease?
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive | 2018 |
Medical Treatment of COPD.
Topics: Adrenal Cortex Hormones; Aminopyridines; Benzamides; Biomimetics; Bronchodilator Agents; Cholinergic Antagonists; Cyclopropanes; Germany; Guideline Adherence; Humans; Medical Overuse; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Theophylline; Treatment Outcome | 2018 |
Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Calcium; CD11b Antigen; Chemokine CXCL1; Chemotaxis, Leukocyte; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Guanine Nucleotide Exchange Factors; Humans; Leukotriene B4; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Rolipram | 2019 |
Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
Topics: Aminopyridines; Animals; Benzamides; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dexamethasone; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation, Bacterial; Haemophilus influenzae; Humans; Inflammation; Lung; Pulmonary Disease, Chronic Obstructive | 2018 |
Drugging the Mighty Neutrophil in Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2019 |
The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Chemokine CCL2; Chemokine CCL4; Cyclopropanes; Female; Humans; Macrophages, Alveolar; Male; Middle Aged; para-Aminobenzoates; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfonamides; Tumor Necrosis Factor-alpha | 2019 |
Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Topics: Aminopyridines; Benzamides; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dinoprostone; Fibroblasts; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Prostaglandin E, EP2 Subtype; RNA, Messenger; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
[Intractable diarrhoea and severe weight loss by roflumilast].
Topics: Aged; Aminopyridines; Animals; Anorexia; Benzamides; Bronchitis; Comorbidity; Cyclopropanes; Diarrhea; Drug Evaluation, Preclinical; Female; Gastrointestinal Tract; Hallucinations; Hospitalization; Humans; Patient Readmission; Phosphodiesterase Inhibitors; Polypharmacy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Sleep Apnea Syndromes; Vomiting; Weight Loss | 2013 |
Concurrent agonism of adenosine A2B and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Algorithms; Aminopyridines; Calcium; Cell Line; Cyclic AMP; Cyclic AMP Response Element Modulator; Cytosol; Dexamethasone; Epithelial Cells; Humans; Inflammation; Phenethylamines; Pulmonary Disease, Chronic Obstructive; Real-Time Polymerase Chain Reaction; Receptor, Adenosine A2B; Receptors, Glucocorticoid; Respiratory Mucosa; RNA, Messenger; Transfection | 2013 |
Response to: Oba, Y. and Lone, N. (2013) Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Ther Adv Respir Dis 7: 13-24.
Topics: Aminopyridines; Benzamides; Female; Humans; Lung; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2013 |
Phenotype/endotype-driven therapy in COPD: potential economic implications.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Forced Expiratory Volume; Humans; Lung; Patient Selection; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Treatment Outcome | 2013 |
Identifying and treating COPD in cardiac patients.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Pulmonary Disease, Chronic Obstructive; Registries | 2013 |
Cardiovascular safety of roflumilast.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2013 |
Response.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2013 |
Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Topics: Adenine; Aminopyridines; Benzamides; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclopropanes; Disease Progression; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Neutrophils; Nicotiana; Phosphodiesterase 4 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Quinazolines; Smoke; U937 Cells | 2014 |
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Logistic Models; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2013 |
Benefits and harms of roflumilast in moderate to severe COPD.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Pulmonary Disease, Chronic Obstructive; Risk Assessment | 2014 |
Evidence roflumilast reduces severe exacerbations?
Topics: Aminopyridines; Benzamides; Disease Progression; Female; Humans; Male; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Response.
Topics: Aminopyridines; Benzamides; Disease Progression; Female; Humans; Male; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Topics: Aged; Aminopyridines; Apoptosis; Benzamides; Bronchi; Cyclic AMP; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Respiratory Mucosa; Smoke; Smoking; Transforming Growth Factor beta1 | 2014 |
Using absolute risks to assess the risks and benefits of treatment.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Aged; Aminopyridines; Benzamides; Biomarkers; Complex Mixtures; Cyclopropanes; Dexamethasone; Drug Resistance; Drug Synergism; Female; Gene Expression; Histone Deacetylases; Humans; Interleukin-8; Intramolecular Oxidoreductases; Lipopolysaccharides; Macrophage Migration-Inhibitory Factors; Male; Matrix Metalloproteinase 9; Middle Aged; Mitogen-Activated Protein Kinase Phosphatases; Neutrophils; Nicotiana; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Primary Cell Culture; Pulmonary Disease, Chronic Obstructive | 2014 |
New therapy for managing moderate to severe chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Multicenter Studies as Topic; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide | 2014 |
Point: were industry-sponsored roflumilast trials appropriate? Yes.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2014 |
Counterpoint: were industry-sponsored roflumilast trials appropriate? No.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2014 |
Rebuttal from Drs Suissa and Rabe.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2014 |
Rebuttal from Dr Rho et al.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2014 |
Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Topics: Adrenergic beta-Agonists; Aged; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Registries; Severity of Illness Index; Treatment Outcome | 2015 |
Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Topics: Adrenal Cortex Hormones; Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchi; Case-Control Studies; Cells, Cultured; Cyclopropanes; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Epithelial Cells; Female; Humans; Interleukin-8; Male; Middle Aged; Poly I-C; Pulmonary Disease, Chronic Obstructive; Signal Transduction; Smoking; Toll-Like Receptor 3 | 2015 |
Dual anti-inflammatory agents prevent COPD exacerbations.
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2015 |
COPD: improving prevention and care.
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pregnancy; Pulmonary Disease, Chronic Obstructive | 2015 |
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Topics: Adenosine; Adrenergic beta-Agonists; Aminopyridines; Analgesics; Benzamides; Bronchi; Cyclic AMP; Cyclopropanes; HEK293 Cells; Humans; Isoproterenol; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Smoking | 2015 |
Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Topics: Aminopyridines; Animals; Benzamides; Catalytic Domain; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Haemophilus influenzae; Humans; Inflammation; Mice; Mice, Inbred C57BL; Phosphorylation; Protein Binding; Pulmonary Disease, Chronic Obstructive; RNA, Small Interfering; Transcription Factor RelA; Up-Regulation | 2015 |
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Aminopyridines; Benzamides; Chi-Square Distribution; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Female; Health Resources; Hospital Costs; Hospitalization; Humans; Linear Models; Male; Medicare Part C; Middle Aged; Models, Economic; Multivariate Analysis; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2015 |
Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Chi-Square Distribution; Cyclopropanes; Databases, Factual; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Readmission; Phosphodiesterase 4 Inhibitors; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States | 2015 |
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Flow Cytometry; Fluticasone; Forced Expiratory Volume; Greece; Humans; Lung; Muscarinic Antagonists; Phagocytosis; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Salmeterol Xinafoate; Spirometry; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Data Collection; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research; Research Design; Risk Assessment | 2015 |
Roflumilast in COPD.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2015 |
Response.
Topics: Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2015 |
Roflumilast in COPD: a Brazilian perspective.
Topics: Aminopyridines; Benzamides; Brazil; Cyclopropanes; Disease Progression; Humans; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2015 |
Does roflumilast induce phagocytic activity in COPD patients?
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Humans; Lung; Phagocytosis; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2015 |
Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; United States | 2015 |
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Topics: Aminopyridines; Animals; Benzamides; Blood Platelets; Cardiovascular Diseases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Extracellular Traps; Fibrinogen; Humans; Leukocytes; Macrophage-1 Antigen; Mice; Microscopy, Confocal; Monocytes; Neutrophils; P-Selectin; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Phosphorylation; Platelet Adhesiveness; Pulmonary Disease, Chronic Obstructive; Risk; Thromboplastin; Thrombosis | 2016 |
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Topics: Aged; Ambulatory Care; Aminopyridines; Benzamides; Cost of Illness; Cyclopropanes; Disease Progression; Female; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Symptom Flare Up; United States | 2015 |
Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cell Line; Chemokines; Chemotaxis; Cyclopropanes; Dinoprostone; Drug Therapy, Combination; Epithelial Cells; Humans; Immunity, Cellular; Leukocyte Elastase; MAP Kinase Signaling System; Neutrophils; Pulmonary Disease, Chronic Obstructive | 2016 |
Respiratory medications.
Topics: Administration, Inhalation; Aminopyridines; Androstadienes; Asthma; Beclomethasone; Benzamides; Cyclopropanes; Humans; Indans; Maleates; Nasal Sprays; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Diseases; Rhinitis, Allergic | 2016 |
Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Load; Benzamides; Bronchoalveolar Lavage Fluid; Chemokines; Colony Count, Microbial; Cyclopropanes; Cytokines; Female; Leukocyte Count; Lung; Mice; Mice, Inbred BALB C; Neutrophils; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections | 2016 |
Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency.
Topics: Aging; Airway Remodeling; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunity, Innate; Immunoglobulin A, Secretory; Leukocyte Elastase; Lung; Matrix Metalloproteinase 12; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbiota; NF-kappa B; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Receptors, Polymeric Immunoglobulin; Respiratory Mucosa | 2016 |
A new two-step algorithm for the treatment of COPD.
Topics: Adrenal Cortex Hormones; Algorithms; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Macrolides; Muscarinic Antagonists; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Medicine | 2017 |
Phosphodiesterase-4 inhibition in COPD.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Therapy, Combination; Humans; Patient Selection; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Treatment Outcome | 2009 |
Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.
Topics: Aminopyridines; Animals; Benzamides; Blotting, Western; Bronchoalveolar Lavage Fluid; Cyclopropanes; Down-Regulation; Immunoenzyme Techniques; Male; Mice; Mice, Inbred AKR; Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Proliferating Cell Nuclear Antigen; Pulmonary Disease, Chronic Obstructive; Smoking; Statistics, Nonparametric; Uteroglobin | 2009 |
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
New evidence in pulmonary and preventive medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Benzamides; Breast Neoplasms; Bronchodilator Agents; Cyclopropanes; Disease Progression; Early Detection of Cancer; Evidence-Based Medicine; Female; Humans; Papillomavirus Vaccines; Preventive Medicine; Primary Prevention; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Secondary Prevention; Tiotropium Bromide; Uterine Cervical Neoplasms | 2010 |
Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Models, Biological; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Approval; Drug Design; Europe; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; United States; United States Food and Drug Administration | 2010 |
Roflumilast.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2010 |
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Topics: Administration, Inhalation; Aminopyridines; Asthma; Binding, Competitive; Drug Design; HEK293 Cells; Humans; I-kappa B Kinase; Indazoles; Isonicotinic Acids; Microsomes, Liver; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Niacinamide; Phenethylamines; Potassium Channel Blockers; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2011 |
[Introduction. COPD treatment].
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forecasting; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
[Pulmonary medicine. Two new drugs for the treatment of COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
[New drugs in chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
[Introduction].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast (Daliresp) for COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Health Services; Health Status; Humans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Reproducibility of Results; Scopolamine Derivatives; Severity of Illness Index; Time Factors; Tiotropium Bromide | 2011 |
[COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Blood Glucose; Cholinergic Antagonists; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Avoiding backward steps in COPD: looking again at roflumilast.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2012 |
[New goals in COPD treatment. From symptom control to prevention of exacerbations].
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Long-Term Care; Phosphodiesterase 4 Inhibitors; Prognosis; Pulmonary Disease, Chronic Obstructive | 2011 |
Side-effects of roflumilast.
Topics: Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2012 |
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Topics: Administration, Oral; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclic AMP; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Algorithms; Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Markov Chains; Models, Economic; Muscarinic Antagonists; Outcome and Process Assessment, Health Care; Phosphodiesterase 4 Inhibitors; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Severity of Illness Index; State Medicine; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification.
Topics: Aminopyridines; Autoimmunity; Benzamides; Bronchodilator Agents; Cholinergic Antagonists; Comorbidity; Cyclopropanes; Drug Synergism; Humans; Immunocompromised Host; Infection Control; Inflammation; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Smoking; Tumor Necrosis Factor-alpha | 2012 |
Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice.
Topics: Administration, Inhalation; Airway Resistance; Aminopyridines; Androstadienes; Animals; Benzamides; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Cyclopropanes; Fluticasone; Forced Expiratory Volume; Ipratropium; Lung; Mice; Pancreatic Elastase; Phosphatidylcholines; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Respiratory Physiological Phenomena; Superoxide Dismutase; Superoxides; Vital Capacity | 2012 |
The potential role of racecadotril in the treatment of diarrhea associated with roflumilast.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aminopyridines; Antidiarrheals; Benzamides; Child; Cyclic AMP; Cyclopropanes; Diarrhea; Humans; Neprilysin; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Thiorphan | 2012 |
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
Topics: Adrenal Cortex Hormones; alpha 1-Antitrypsin; Aminopyridines; Anti-Bacterial Agents; Asthma; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Comorbidity; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Expectorants; Humans; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Respiratory System Agents; Severity of Illness Index; Spain; Theophylline | 2012 |
Dear Dr. Walson.
Topics: Aminopyridines; Animals; Benzamides; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2012 |
[Chronic obstructive pulmonary disease : new pharmacotherapeutic options].
Topics: Adrenal Cortex Hormones; Aminopyridines; Benzamides; Cholinergic Antagonists; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive | 2012 |
[Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Leukocytes; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2012 |
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Cells, Cultured; Chemotaxis; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dinoprostone; Fibroblasts; Fibronectins; Gene Expression; Humans; Iloprost; Isoenzymes; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP2 Subtype; Rolipram; Second Messenger Systems | 2012 |
Roflumilast: doubtful efficacy but clear harms in COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Drug Approval; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2013 |
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2013 |
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Hospitalization; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Econometric; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Severity of Illness Index; Switzerland | 2013 |
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary di
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cells, Cultured; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Ethanolamines; Female; Formoterol Fumarate; Glucocorticoids; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Transcription, Genetic; Treatment Outcome | 2013 |
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Topics: Age Factors; Aged; Aminopyridines; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclopropanes; Delayed-Action Preparations; Female; Health Services; Humans; Male; Markov Chains; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Respiratory Function Tests; United Kingdom | 2014 |
[Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2004 |
Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Drug Evaluation, Preclinical; Humans; Lipopolysaccharides; Molecular Structure; Phosphodiesterase Inhibitors; Phthalazines; Pulmonary Disease, Chronic Obstructive; Rolipram; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2004 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Attitude of Health Personnel; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Failure | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Forced Expiratory Flow Rates; Humans; Inflammation; Pulmonary Disease, Chronic Obstructive; Smoking | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Attitude of Health Personnel; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive | 2005 |
Roflumilast for asthma and chronic obstructive pulmonary disease.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2005 |
Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Anti-Inflammatory Agents; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Lung Diseases; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Ventilation; Randomized Controlled Trials as Topic | 2006 |